Journal
JOURNAL OF MOLECULAR DIAGNOSTICS
Volume 22, Issue 7, Pages 943-956Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmoldx.2020.04.206
Keywords
-
Categories
Funding
- Foerdergesellschaft Stiftung Tumorbiologie, Freiburg, Germany
- Comprehensive Cancer Center Freiburg research grant
- German Research Foundation [CRC-850]
- German Federal Ministry of Education and Research [FKZ 01ZX1708F]
- Deutsche Gesellschaft fur Hamatologie und Medizinische Onkologie e. V. (DGHO)eGesellschaft fur Medizinische InnovationeHamatologie und Onkologie mbH (GMIHO)
Ask authors/readers for more resources
Detection and quantification of tumor-derived KRAS and NRAS mutations in plasma cell-free DNA (cfDNA) holds great potential for cancer diagnostics and treatment response monitoring. Because of high sensitivity, specificity, robustness, and affordability, digital droplet PCR (ddPCR) is ideally suited for this application but requires discriminatory multiplexing when used as screening assay. We therefore designed, optimized, and clinically validated mutation-specific locked nucleic acid-based ddPCR assays for 14 commonly occurring KRAS and NRAS mutations and assembled these assays into seven discriminatory multitarget screening assays covering two to six single-nucleotide variants each. Limit of detection, limit of blank, and interassay accuracy were determined. Assay performance and suitability for screening in cfDNA were validated with plasma samples from a clinically fully characterized cohort of pancreatic cancer patients and healthy controls. Limits of detection for single-target assays were between 0.0015% and 0.069% variant allele fraction, and between 0.022% and 0.16% for multitarget assays. Dilution linearity and interassay accuracy were excellent throughout (r(2) > 0.99). Multitarget assay screening of cfDNA extracted from pancreatic cancer patients with unknown KRAS mutational status correctly identified single-nucleotide variants in 45 of 45 (100%) of tumor-derived cell-free DNA - positive samples. In summary, we herein present and clinically validate generic single-target and discriminatory multitarget ddPCR assays for KRAS and NRAS hot spot mutations with broad applicability for clinical and translational research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available